Postprandial Secretion of of Incretin Hormones and Incretin Effect in Patients With Maturity-onset Diabetes of the Young (MODY)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 31
- Locations
- 1
- Primary Endpoint
- Incretin effect
Study Overview
Brief Summary
The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In sulphonyl urea treated subjects the purpose is also to compare the incretin effect with and without treatment. In healthy subjects the purpose is also to investigate the incretin effect under increased levels of endogen incretin hormones.
Detailed Description
Comparison of of insulin secretion (AUC) during the experimental days. Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Caucasians above 18 years
- •BMI > 19 kg/m2
- •Negative pancreatic beta cell- and glutamate decarboxylase-65(GAD65)- autoantibodies
- •Normal haemoglobin
- •Normal bloodpressure
- •Informed concent
Exclusion Criteria
- •Known liver disease or affected liver enzymes (ALAT/ASAT >2 x upper normal limit)
- •Nephropathy (see creatinine> 130 μM and / or albuminuria)
- •Treatment with medications that cannot be discontinued for 12 hours
- •Any condition that the investigators feel would interfere with trial participation
- •Pregnancy or lactation
Outcomes
Primary Outcomes
Incretin effect
Time Frame: Within 1 year
The difference in insulin responses, as assessed by the area under curve (AUC) for plasma insulin and C-peptide concentrations, during the two different glucose stimuli: OGTT and isoglycemic iv glucose infusion aswell as after a test meal in MODY-patients compared to healthy control subjects.
Secondary Outcomes
- Plasma GLP1 response(Within 1 year)
- Plasma GIP response(Within 1 year)
- Plasma glucagon response(Within 1 year)
Investigators
Signe H Østoft, MD
MD
University Hospital, Gentofte, Copenhagen